慢性粒细胞白血病疾病转化及停药的研究进展  

Progress of disease transformation and drug discontinuation in chronic myeloid leukemia

作　　者：江佩芳 胡建达[1] Jiang Peifang;Hu Jianda(Department of Hematology,Fujian Medical University Union Hospital,Fujian Provincial Key Laboratory of Hematology,Fujian Institute of Hematology,Fuzhou 350001,China)

机构地区：[1]福建医科大学附属协和医院血液科,福建省血液病学重点实验室,福建省血液病研究所,福州350001

出　　处：《白血病．淋巴瘤》2021年第3期137-140,共4页Journal of Leukemia & Lymphoma

摘　　要：自BCR-ABL融合基因的鉴定和针对性的酪氨酸激酶抑制剂(TKI)问世后,慢性粒细胞白血病(CML)患者已经在慢病化的道路上“行走”了约二十年。近年来,二代、三代TKI为CML患者的长期生存提供了进一步的保障。但TKI停药和少数TKI耐药或携带不良预后基因患者的预后情况仍是CML相关研究的热点问题。文章对2020年第62届美国血液学会年会上关于CML研究进展的报道作一介绍。Since the identification of BCR-ABL fusion gene and the advent of targeted tyrosine kinase inhibitors(TKI),patients with chronic myeloid leukemia(CML)have been"walking"on the path of chronic disease for around twenty years.In recent years,the second-and third-generation TKI have provided further protection for the long-term survival of CML patients.However,TKI discontinuation and the prognostic situation of a small number of patients with TKI resistance or carrying poor prognostic genes are still hot issues in CML-related researches.This article reviews the research progress of CML at the 62nd American Society of Hematology Annual Meeting.

关 键 词：白血病 髓系 慢性 BCR-ABL阳性 酪氨酸激酶抑制剂 预后 

分 类 号：R733.72[医药卫生—肿瘤]